CHROMOSOMAL-ABERRATIONS AND MICRONUCLEUS FREQUENCY IN NURSES OCCUPATIONALLY EXPOSED TO CYTOTOXIC DRUGS

被引:45
作者
ANWAR, WA
SALAMA, SI
ELSERAFY, MM
HEMIDA, SA
HAFEZ, AS
机构
[1] NATL RES CTR,COMMUNITY RES DEP,CAIRO,EGYPT
[2] NATL CANC INST,DEPT INTERNAL MED & MED ONCOL,CAIRO,EGYPT
关键词
D O I
10.1093/mutage/9.4.315
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
In this study, we evaluated the effect of low level occupational exposure of nurses in a medical oncology unit in Cairo, Egypt, to anticancer drugs. Twenty nurses who constantly handled these drugs and 20 controls, matched according to age and sex, were examined. Metaphase chromosomes were studied. Percentages of metaphases with chromosomal aberrations were significantly higher (P < 0.001) in the exposed group (6.1 +/- 2.7) versus the controls (2.6 +/- 1.6). The detected chromosomal aberrations were in the form of chromatid gaps, chromatid breaks and acentric fragments. Micronucleated peripheral blood lymphocytes were also analyzed in cytochalasin B treated binucleated lymphocytes. There was significant increase in cells with micronuclei (P < 0.001) in nurses (10.05 +/- 4.71) in comparison to the matched control (5.42 +/- 2.22) (P < 0.001). Nurses exposed to the cytotoxic drugs for greater than or equal to 48 months showed a slightly higher frequency of cells with chromosomal aberrations as well as micronucleated cells than those exposed for <48 months, but these differences were not statistically significant (P > 0.05).
引用
收藏
页码:315 / 317
页数:3
相关论文
共 25 条
[21]   BIOLOGICAL AND ENVIRONMENTAL MONITORING OF OCCUPATIONAL EXPOSURE TO CYCLOPHOSPHAMIDE IN INDUSTRY AND HOSPITALS [J].
SORSA, M ;
PYY, L ;
SALOMAA, S ;
NYLUND, L ;
YAGER, JW .
MUTATION RESEARCH, 1988, 204 (03) :465-479
[22]  
STAIANO N, 1981, LANCET, V1, P615
[23]   NO ELEVATION OF THE FREQUENCIES OF CHROMOSOMAL ALTERATIONS AS A CONSEQUENCE OF HANDLING CYTOSTATIC DRUGS - ANALYSES WITH PERIPHERAL-BLOOD AND URINE OF HOSPITAL PERSONNEL [J].
STILLER, A ;
OBE, G ;
BOLL, I ;
PRIBILLA, W .
MUTATION RESEARCH, 1983, 121 (3-4) :253-259
[24]  
VENNIT S, 1984, LANCET, V1, P74
[25]  
WAKSVIK H, 1981, CANCER TREAT REP, V65, P607